Flamel Technologies S.A. (ADR)

Deerfield raises stake in Flamel Technologies to 17.58% from 5.11%

Flamel Shares Flamed Out: What You Need to Know

James E. Flynn reports 5.11% stake in Flamel Technologies

Flamel Technologies reports Q3 EPS 7c vs. consensus (9c)

Flamel Technologies Announces Profitable Third Quarter Results

Flamel Technologies Announces Projected Release Date of Third Quarter Results; Conference Call

Flamel Technologies announces multi-year supply agreement with GlaxoSmithKline

Flamel Technologies Announces Multi-Year Supply Agreement with GlaxoSmithKline for Coreg CR™ Microparticles

Flamel Technologies, Eagle Pharma enter into license and development agreement

Eagle Pharmaceuticals and Flamel Technologies Announce Eagle to License Medusa Technology for Extended-Release of Tigecycline

Deerfield Capital reports 5.0% passive stake in Flamel Technologies

Flamel Technologies reports Q2 EPS (14c) vs. consensus (9c)

Flamel Technologies Announces Projected Release Date of Second Quarter Results; Conference Call

Flamel Technologies, Digna announce multiple product development agreement

Flamel Technologies: Elie Vannier to continue to serve as non-executive Chairman

Flamel Technologies reports Q1 EPS (20c) vs. consensus (11c)

Flamel Technologies Announces Projected Release Date of First Quarter Results; Conference Call

Flamel Technologies announces license agreement for Micropump

Flamel Technologies reports Q4 EPS 11c vs. consensus 5c

Flamel Technologies Announces Projected Release Date of Fourth Quarter and Annual Results; Conference Call

Flamel Technologies March calls active at elevated prices on sharp rally

Trading European Volatility: The Options Market's Top 8 European Stock Picks

Flamel Technologies reports Q3 EPS (14c) vs. consensus 0c

Flamel Technologies Announces Third Quarter Results; Achievement of Second Milestone in Fourth Quarter with Merck Serono

Flamel Technologies Announces Projected Release Date of Third Quarter Results; Conference Call

Flamel Tech announces clinical milestone with Merck Serono

Flamel Technologies Achieves Clinical Milestone with Merck Serono on an Extended Release Formulation of Interferon beta-1a

Flamel Continues to Add New Projects to Its Pipeline

These Stocks Will Bite You

Flamel Technologies to Present at the UBS Global Life Sciences Conference in New York

Flamel Technologies initiated with a Buy at Roth Capital

Flamel Technologies SA Q2 2010 Earnings Call Transcript

Flamel Technologies reports Q2 EPS (18c) vs. consensus of (5c)

Foreign Stocks You Can Actually Buy: France

Flamel Technologies initiated with a Buy at Roth Capital

Flamel Technologies reports Q1 EPS (17c) vs. consensus of (13c)

Visium reports 7.64% passive stake in Flamel Technologies

O.S.S. Capital reports 13.42% passive stake in Flamel Technologies

Zacks #5 Rank Additions for Monday - Zacks Tale of the Tape

Flamel Technologies reports Q4 EPS (23c) vs. consensus of (10c)